Androgen receptor as a therapeutic target for androgen independent prostate cancer

Nima Sharifi, William L. Farrar

Research output: Contribution to journalReview articlepeer-review

34 Scopus citations


Prostate cancer is the leading cause of nonskin malignancy and the second leading cause of cancer death in men. Androgen deprivation therapy is the first-line of systemic therapy against advanced prostate cancer. All advanced prostate cancers eventually grow despite castrate levels of testosterone. We review the evidence that androgen independent prostate cancer continues to require androgen receptor activity for growth, the mechanisms of androgen receptor activation in the castrate setting, and possible points of intervention for novel therapies targeting the androgen receptor and prostate cancer.

Original languageEnglish (US)
Pages (from-to)166-170
Number of pages5
JournalAmerican Journal of Therapeutics
Issue number2
StatePublished - Mar 1 2006


  • Androgen receptors
  • Genes
  • Medical oncology
  • Prostatic neoplasms

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Androgen receptor as a therapeutic target for androgen independent prostate cancer'. Together they form a unique fingerprint.

Cite this